David Berman, MD, PhD, discusses signs of dose-dependent viral control and reduction in active HIV reservoir in Phase 1/2 STRIVE trial data.
David Berman, MD, PhD
Advertisement
Executive Vice President of Research and Development at Immunocore.
Articles by David Berman, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
Initiatives Look to Strengthen Vaccine Policy and Governance in US
2
European Commission Approves Glecaprevir/Pibrentasvir for Hepatitis C
3
Infectious Disease Regulatory Watch: June Highlights
4
Efflux Pump Inhibitor Restores Azithromycin Activity Against Multidrug-Resistant Gram-Negative Pathogens
5